Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OSE 2101

Next Previous
Drug Profile

OSE 2101

Alternative Names: EP-2101; IDM 2101; OSE-2101; Tedopi

Latest Information Update: 18 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IDM Pharma
  • Developer ARCAGY/GINECO Group; Bristol-Myers Squibb; GERCOR; OSE Immunotherapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 11 Sep 2025 OSE Therapeutics, FoRT Foundation and Bristol Myers Squibb completes enrolment in the phase II COMBI-TED trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France, Italy, Spain (SC) (NCT04884282)
  • 02 Jun 2025 Efficacy and adverse events data from a phase II trial in Pancreatic cancer released OSE Immunotherapeutics
  • 17 Apr 2025 OSE Immunotherapeutics plans a phase II trial for Non small cell lung cancer (Combination therapy, Metastatic disease, Late stage disease, Second line therapy or greater) in Italy (Injection) (CTIS2024-519262-42-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top